Response to Rituximab after Failure of Cyclophosphamide in the Induction Treatment in a Patient with cANCA-associated Vasculitis and Pachymeningitis: a Case Report by O. Psenak  et al.
С О В P E М Е Н Н А Я  Р Е В М А Т О Л О Г И Я  № 4 ’ 2 1
К Л И Н И Ч Е С К И Е  Н А Б Л Ю Д Е Н И Я  /  C L I N I C A L  O B S E R V A T I O N S
68Современная ревматология. 2021;15(4):68–71
Introduction
Granulomatosis with polyangiitis (GPA) is a necrotizing vas-
culitis affecting small and medium-sized vessels, associated with
antineutrophil cytoplasmic antibodies with cytoplasmic
immunofluorescence pattern (cANCA) directed against pro-
teinase 3 (PR3). It is a very heterogeneous disease as to localiza-
tion, extent, severity and clinical manifestations. It can be limited
to one organ or local tissue only (nasal or oral mucosa), however
it can rapidly progress to a systemic disease (ocular, lung, renal or
nervous system involvement) with lethal outcome, if untreated or
treated improperly. Diagnosis is made by clinical presentation,
positivity of cANCA and the presence of typical histologic find-
ings (vascular necrosis or granuloma) [1]. Local manifestations
can be treated with cotrimoxazole or methotrexate [2, 3], the
extended disease should be treated either with cyclophosphamide
(CYC) or rituximab that has been shown to be non-inferior in
cANCA-positive vasculitis [4, 5]. Life-threatening conditions can
be managed using plasmapheresis [6]. Induction treatment usual-
ly consists of at least 6 cycles of CYC or 3–4 cycles of rituximab
[5, 7], accompanied by Pneumocystis jirovecii prophylaxis with
cotrimoxazole due to increased prevalence of this infection in the
acute phase of the disease [8]. Rituximab has also been shown to
be effective in less frequent manifestations of the disease such as
pachymeningitis [9]. After remission, maintenance treatment is
recommended to avoid a relapse or recurrence of vasculitis.
Traditionally, two immunosuppressants used to be given: either
azathioprine or methotrexate, the first is preferred in reduced
glomerular filtration rate [10]. However, the MAINRITSAN trial
demonstrated better outcomes using rituximab than azathioprine
in the maintenance setting [11]. Maintenance treatment should
last 18–24 months [12].
We present a patient with less common manifestations of
ANCA-positive GPA comprising otitis media, peripheral facial
palsy, orbital involvement, sterile meningitis, infiltration of the
parapharyngeal tissue, pterygoid muscle as well as tissue around
the internal carotid who was refractory to 5 administrations of
CYC. However, after switching the induction therapy to rituximab,
nearly complete remission of the above mentioned manifestations
was achieved. As reports of such course of the disease are scarce,
we would like to contribute to medical literature to encourage
physicians to use rituximab in unusual manifestations of GPA.
Case report
A 36-year-old male patient developed tympanic cavity effu-
sion, treated with paracentesis and drainage. This was followed
by multiple operations due to recurrent otitis media; additional-
ly a peripheral facial palsy developed on the right side. Due to
recurrent fibrosing bilateral otitis, complicated by left facial
palsy, mastoidectomy was performed. Atypical mycobacterial
infection was assumed and antibiotic treatment with ethambu-
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tol, moxifloxacin and clarithromycin was
prescribed. However, this infection was
not confirmed.
Several months later, the patient pre-
sented at hospital with poor physical fit-
ness, body weight loss of 15 kg and sudden
decline of muscle strength in the right
arm. Cerebral computed tomography
(CT) showed small subdural haematoma
on the right side. Additionally, right medi-
an nerve paralysis developed and the
patient was transferred to the intensive
care unit. Due to febrile infection with
Staphylococcus aureus, detected in the
blood culture, linezolid and ceftriaxone
were administered. Cerebral magnetic
resonance tomography (MRT) showed a
thickening of the dura mater (4 mm) of
the right hemisphere corresponding to
meningitis. This condition was interpreted
as a consequence of the otitis media. Transoesophageal echocar-
diography did not show endocarditis.
In the meantime, high titres of antineutrophil cytoplasmic
antibodies with cytoplasmic immunofluorescence pattern
(cANCA) directed against proteinase 3 (PR3) were detected in
extended laboratory examinations (1:160). Increased inflamma-
tory markers were detected (normal range in round brackets):
leucocytes 14 800/μl (4300–10 000/μl), ESR (erythrocyte sedi-
mentation rate) 87/95 mm/h (0–15 mm/h), CRP (C-reactive
protein) 193.4 mg/l (0–5.0 mg/l). Furthermore, anaemia with
haemoglobin 11.8 g/dl (14.0–17.5 g/dl), creatinkinase 20 U/l
(38–174 U/l), rheumatoid factor 28 U/ml (0–14 U/ml), creati-
nine 0.63 mg/dl (0.7–1.2 mg/dl), as well as elevated liver
enzymes were found.
Though histological analyses of the above mentioned inflam-
matory processes in the middle ear did not show granulomatous
changes, the patient’s condition was ascribed to cANCA-associ-
ated vasculitis with sterile meningitis as the cerebrospinal fluid
did not demonstrate signs of a purulent bacterial infection.
Similar cases of cANCA-associated vasculitis with otitis media
have already been described [13]. Neither renal involvement
(urine protein analysis) nor pulmonary manifestation (CT exami-
nation) could be found. Via gastroscopic and endosonographic
examinations a 2.5 cm large GIST (gastrointestinal stromal
tumor) in the cardia of the stomach was suspected. An extended
faecal examination did not confirm parasites.
Based on these findings, induction therapy with daily oral
prednisolone 1 mg/kg body weight was introduced [14].
Additionally, cyclophosphamide (CYC) 750 mg/m2 of body sur-
face i.v. with urocystitis prophylaxis with mesna was started. CYC
was repeated every 4 weeks [15] instead of CYCLOPS protocol
because of inconvenience of frequent hospital visits for the
patient due to a far distance between his home and the university
hospital. Gabapentin was added to ease the neuropathic pain in
the forearm and the patient received physiotherapy to improve his
fitness and muscle strength. Pneumocystis jirovecii (PJ) prophy-
laxis with oral cotrimoxazole three times per week was given as
well. Prednisolone was tapered by 5 mg every week. During the
induction treatment, nausea, chest pain, ocular pain, paraesthe-
sias in the fingers, arthralgias as well as recurrent urticaria on the
neck and forearms were reported and ascribed to side effects of
CYC. Furthermore, painful bleeding ulcer-
ations on the tips of unilateral fingers 2 and
3, associated with cold acra, developed
5–6 months after initiation of the induc-
tion treatment. Oscillography detected
perfusion defects that improved on sub-
lingual nitroglycerin administration [16].
Antiphospholipid screening was negative.
A vasodilatative therapy with iloprost, ini-
tially 10 μg, followed by 20 μg was intro-
duced: the first cycle consisting of 7 infu-
sions, the second and third cycle 4 weeks
apart each consisting of 5 infusions, 
followed by further separate infusions
every 4 weeks [17]. 
Controlled MRT, performed 5 months
after the first infusion of CYC, showed
increasing thickness of the right-side dura
mater (6 mm) and increasing infiltration
of the right orbit associated with slight
exophthalmus. Infiltration of the parapharyngeal tissue, pterygoid
muscle, tissue around the right internal carotid and bilateral oblit-
eration of the mastoid remained unchanged (Fig. 1.). 
This condition was classified as progressive disease, and taking
into account the intolerance reactions, as mentioned above, the
induction therapy was changed after 5 cycles of CYC to rituximab
i.v., administered at a dose of 1000 mg two weeks apart and
repeated every 6 months [18]. Additionally, prednisolone was
increased to 1 mg/kg body weight again. Four months after this
treatment switch, atypical resection of the stomach was per-
formed; the initially suspected GIST lesion was not confirmed,
the histologic analysis showed leiomyoma. 
Four months after the first cycle of rituximab, MRT con-
trolled examination showed significant reduction of the pachy-
meningitis and other findings described above; the bilateral oblite-
ration of the mastoid remained stable. After 22 infusions with ilo-
prost, complete remission of digital ulcerations achieved and ilo-
prost was stopped. During rituximab administration, the patient
reported arthralgias in large joints, cephalea, fatigue, sleeplessness
as well as paraesthesias in the right foot. As the arthralgias did not
improve, we assumed a joint manifestation of the underlying disease
and adjusted the dose of prednisolone temporarily and added 
20 mg of oral methotrexate (MTX) per week, 16 months after 
initiation of the induction treatment with CYC [19]. MTX was
well tolerated, neurologic symptoms on the right foot improved.
After the 3rd cycle of rituximab, further regression of pachy-
meningitis, tissue infiltrations as well as reduction of exophthal-
mus were confirmed by MRT examination (Fig. 2 and 3). 
The mastoid obliteration remained unchanged. Regression
and, finally, remission of meningitis were observed on the MRT
scans after the 5th cycle of rituximab. Magnetic resonance
angiography did not confirm morphologic changes in the vessels
typically seen in cerebral vasculitis [20].
Up to now, our patient has received 7 cycles of rituximab
(each comprising two infusions with 1000 mg). Cotrimoxazole has
been discontinued. The patient suffers from intermittent arthral-
gias. Repeated laboratory examinations did not confirm any
pathologic changes with respect to the underlying disease: no
changes in blood count, no ANCAs, no inflammation markers, no
proteinuria. At the next check-up we are planning to perform
cerebral MRT to confirm the sustained remission in order to
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Fig. 1. Cerebral MRT. Thickening of the
right dura mater (lower arrow), orbital in-
filtration (middle arrow) and exophthal-
mus (upper arrow) after 5 cycles of CYC.
Progressive disease
introduce a maintenance treatment. This will be performed either
with MTX or with rituximab for the next 18–24 months, as pub-
lished and recommended previously [10, 11]. Currently, the
patient takes the following medications: methotrexate 20 mg per
week, folic acid 5 mg on the 3rd and 4th day after MTX, pred-
nisolone 5 mg per day, vitamin D3 30 drops per week, gabapentin
600 mg three times per day and acetylsalicylic acid 100 mg per day.
Discussion
We demonstrate a successful treatment of a patient with
cANCA-associated vasculitis, who initially presented with
otorhinolaryngologic complications and sterile pachymeningitis.
Due to missing response to CYC we switched the induction thera-
py to rituximab that confirmed its positive effects on the above
mentioned manifestations, which is in concordance with pub-
lished observations. This case confirms the experience and 
recommendations of many physicians that rituximab may be the
drug of choice in induction setting of cANCA-associated vasculi-
tis as it shows very good efficacy and better safety than CYC even
in atypical manifestations involving the central nervous system.
Conclusions
We have demonstrated a complete remission on RTX in a
patient with cANCA-associated vasculitis and sterile pachy-
meningitis refractory to 5 cycles of CYC in the induction treat-
ment. RTX has been well tolerated.
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